• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

EMA

Trikafta/Kaftrio: World’s First Triple Therapy for Cystic Fibrosis
Posted inNew Drugs, Rare/Orphan Diseases, Regulatory

Trikafta/Kaftrio: World’s First Triple Therapy for Cystic Fibrosis

December 9, 2021September 8, 2022

The combination drug will help almost all cystic fibrosis patients.

dwarf family
Posted inNew Drugs, Rare/Orphan Diseases, Regulatory

Voxzogo: First Drug to Treat Dwarfism

December 6, 2021September 8, 2022

Vosoritide by BioMarin Pharmaceutical may cure achondroplasia.

Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Kesimpta: Highly Effective New Drug for Multiple Sclerosis

June 4, 2021September 8, 2022

Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis

April 21, 2021September 8, 2022

Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.

Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory

Zolgensma: Gene Therapy That Cure Spinal Muscular Atrophy. The Most Comprehensive Review

April 8, 2021September 8, 2022

Novartis revealed the most expensive drug in the world. And it is amazing.

Multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis

April 1, 2021September 8, 2022

Siponimod released by Novartis is an improved version of Gilenya.

Enhertu: Most Powerful Drug to Treat Advanced HER2-Positive Breast Cancer
Posted inNew Drugs, Oncology, Regulatory

Enhertu: Most Powerful Drug to Treat Advanced HER2-Positive Breast Cancer

March 31, 2021September 8, 2022

Trastuzumab deruxtecan, developed by AstraZeneca and Daiichi Sankyo, will save lives when Herceptin, Perjeta, and Kadcyla haven’t worked.

Posts navigation

Newer posts 1 2 3 4 Older posts
BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News